Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001312224 | SCV000623371 | likely benign | Renal cell carcinoma | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000570024 | SCV000673731 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-06 | criteria provided, single submitter | clinical testing | The p.R413H variant (also known as c.1238G>A), located in coding exon 2 of the MET gene, results from a G to A substitution at nucleotide position 1238. The arginine at codon 413 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mendelics | RCV000527361 | SCV000838248 | uncertain significance | Papillary renal cell carcinoma type 1 | 2018-07-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001576084 | SCV001803199 | uncertain significance | not provided | 2023-02-06 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with a history of breast cancer (Guindalini et al., 2022); This variant is associated with the following publications: (PMID: 35264596) |